4 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow Aronora, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis AB002 Dose 1, AB002 Dose 2, placebo - End Stage Renal Disease, Thrombosis | Phase 2 | Completed | Aronora, Inc. | 40 | 2019-07-03 | 2024-03-07 |
| Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis AB023- Dose 1, AB023-Dose 2, placebo - End Stage Renal Disease, Thrombosis | Phase 2 | Completed | Aronora, Inc. | 27 | 2018-10-29 | 2024-03-07 |
| Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects E-WE Thrombin- Dose 1, E-WE Thrombin- Dose 2, E-WE Thrombin- Dose 3 - Thrombosis | Phase 1 | Completed | Aronora, Inc. | 21 | 2018-05-30 | 2019-10-29 |
| Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects xisomab 3G3- Dose 1, xisomab 3G3-Dose 2, xisomab 3G3-Dose 3 - Thrombosis | Phase 1 | Completed | Aronora, Inc. | 21 | 2017-06-05 | 2019-06-05 |
Thrombosis (4) · Kidney Failure, Chronic (2)
United States (4)
PMID 31977000, PMID 30700130, PMID 34086880, PMID 38189593, PMID 39060370